Thrombocytopenia   

Is the thrombotic risk associated with TPO-RAs only relevant to VTE or does it also apply to arterial thromboses and stroke? Can the risk be mitigated...

What if there is continued thrombocytopenia despite reaching complete remission (with incomplete marrow recovery)?

Such as the case in which a patient is unresponsive to steroids, IVIG, TPO-agonist, rituximab, splenectomy, and even fostamitinib.

Presuming strong indication for ASA - eg history of NSTEMI

e.g. DITP from eptifibatide after a cardiac intervention

IVIG, TPO, or other agents?

How often do you monitor ADAMTS-13 levels off therapy?

For example, do we prefer one regimen over the other in patients with a bleeding history or who have relapsed after a lengthy remission?

Does having a concurrent consumptive process e.g. DIC change your management? 

Would you consider high-dose dexamethasone (deliberating adverse effects of antenatal steroids) or move to next-line therapies?